ArticleTomography (Ann Arbor, Mich.)2017
Monitoring Radiation Treatment Effects in Glioblastoma: FLAIR Volume as Significant Predictor of Survival.
Article in Tomography (Ann Arbor, Mich.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Prognostic and predictive impact of abnormal signal volume evolution early after chemoradiotherapy in glioblastoma.Journal of neuro-oncology · 2023Trial
- Monitoring glioblastoma dynamics during chemoradiation on the 1.5 T magnetic resonance imaging-linear accelerator.Clinical and translational radiation oncology · 2026Article
- Prognostic impact of RANO resect group classification post-chemoradiotherapy in IDH-wildtype glioblastoma.Journal of neuro-oncology · 2026Article
- Article
- Radiomics and comparative neuroimaging of canine gliomas and human glioblastomas: a step toward precision medicine.Frontiers in veterinary science · 2026Article
- Defining occult disease in glioblastoma using spectroscopic MRI: implications for clinical target volume delineation.Radiation oncology (London, England) · 2025Article
- Magnetic resonance imaging in glioblastoma radiotherapy - beyond treatment adaptation.Physics and imaging in radiation oncology · 2025Article
- Mathematical modeling for glioblastoma treatment: scenario generation and validation for clinical patient counseling.Frontiers in oncology · 2025Article
- Predictive value of magnetic resonance imaging radiomics-based machine learning for disease progression in patients with high-grade glioma.Quantitative imaging in medicine and surgery · 2023Article
- Review
- Radio-Pathomic Maps of Cell Density Identify Brain Tumor Invasion beyond Traditional MRI-Defined Margins.AJNR. American journal of neuroradiology · 2022Article
- Predicting the true extent of glioblastoma based on probabilistic tractography.Frontiers in neuroscience · 2022Article
- Parametric Response Mapping of FLAIR MRI Provides an Early Indication of Progression Risk in Glioblastoma.Academic radiology · 2021Article
- Multi-parametric and multi-regional histogram analysis of MRI: modality integration reveals imaging phenotypes of glioblastoma.European radiology · 2019Article
- Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study.Integrative cancer therapiesObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is the most common adult central nervous system malignancy and carries a poor prognosis. Disease progression and recurrence after chemoradiotherapy are assessed via serial magnetic resonance imaging sequences. T2-weighted fluid-attenuated inversion recovery (FLAIR) signal is presumed to represent edema containing microscopic cancer infiltration. Here we assessed the prognostic impact of computerized volumetry of FLAIR signal in the peri-treatment setting for glioblastoma. We analyzed pre- and posttreatment FLAIR sequences of 40 patients treated at the Columbia University Medical Center between 2011 and 2014, excluding those without high-quality FLAIR imaging within 2 weeks before treatment and 60 to 180 days afterward. We manually contoured regions of FLAIR hyperintensity as per Radiation Therapy Oncology Group guidelines and calculated the volumes of nonenhancing tumor burden. At the time of this study, all but 1 patient had died. Pre- and posttreatment FLAIR volumes were assessed for correlation to overall and progression-free survival. Larger post-treatment FLAIR volumes from sequences taken between 60 and 180 days after conclusion of chemoradiotherapy were negatively correlated with overall survival (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.